<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="reviewer-report"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>j. fac. pharm. ankara</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Journal of Faculty of Pharmacy of Ankara University</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">1015-3918</issn>
                                        <issn pub-type="epub">2564-6524</issn>
                                                                                            <publisher>
                    <publisher-name>Ankara University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.33483/jfpau.1601864</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Pharmacy Management</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Eczacılık İşletmeciliği</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>MARKET ACCESS FOR PHARMACEUTICALS IN TÜRKİYE: A COMPREHENSIVE OVERVIEW</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="tr">
                                    <trans-title>TÜRKİYE’DE İLAÇLARIN PAZARA ERİŞİMİ: KAPSAMLI BİR İNCELEME</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-6967-7496</contrib-id>
                                                                <name>
                                    <surname>Erdağ</surname>
                                    <given-names>Ebru</given-names>
                                </name>
                                                                    <aff>HACETTEPE ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-5217-8797</contrib-id>
                                                                <name>
                                    <surname>Yeğenoğlu</surname>
                                    <given-names>Selen</given-names>
                                </name>
                                                                    <aff>HACETTEPE ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20250519">
                    <day>05</day>
                    <month>19</month>
                    <year>2025</year>
                </pub-date>
                                        <volume>49</volume>
                                        <issue>2</issue>
                                        <fpage>579</fpage>
                                        <lpage>589</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20241216">
                        <day>12</day>
                        <month>16</month>
                        <year>2024</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20250212">
                        <day>02</day>
                        <month>12</month>
                        <year>2025</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1971, Journal of Faculty of Pharmacy of Ankara University</copyright-statement>
                    <copyright-year>1971</copyright-year>
                    <copyright-holder>Journal of Faculty of Pharmacy of Ankara University</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>Objective: This study provides a detailed analysis of the market entry processes for pharmaceuticals in Türkiye, examining the key factors shaping these processes and their alignment with international standards. The aim is to highlight the significance of regulatory mechanisms, economic strategies, and health technology assessment (HTA) in ensuring patients&#039; access to high-quality medicines.Result and Discussion: The pharmaceutical sector in Türkiye has evolved into a dynamic and growing industry, supported by significant contributions from both domestic and international stakeholders. Regulatory advancements, such as the establishment of the Turkish Medicines and Medical Devices Agency (TİTCK), have improved licensing, pricing, and reimbursement processes, aligning them with international practices. Additionally, HTA has emerged as a critical tool in evidence-based decision-making, optimizing the efficient use of healthcare resources and supporting sustainable access to innovative treatments. However, to maintain their effectiveness, these processes require continuous updates and improvements. Such efforts will provide significant benefits not only to the industry but also to patients and society as a whole.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="tr">
                            <p>Amaç: Bu çalışma, Türkiye’deki ilaçların piyasaya giriş süreçlerini ayrıntılı bir şekilde inceleyerek, bu süreçleri şekillendiren ana unsurları ve uluslararası standartlarla olan uyum düzeylerini ele almaktadır. Çalışmanın hedefi, düzenleyici mekanizmaların, ekonomik stratejilerin ve sağlık teknolojisi değerlendirmesinin (STD), hastaların kaliteli ilaçlara erişimini sağlamadaki önemini ortaya koymaktır.Sonuç ve Tartışma: Türkiye&#039;deki ilaç sektörü, yerli ve yabancı paydaşların önemli katkılarıyla dinamik ve gelişen bir endüstri haline gelmiştir. Türk İlaç ve Tıbbi Cihaz Kurumu’nun (TİTCK) kurulması gibi düzenleyici yenilikler, ruhsatlandırma, fiyatlandırma ve geri ödeme süreçlerini geliştirerek uluslararası standartlarla uyumlu hale getirmiştir. Bunun yanı sıra, sağlık teknolojisi değerlendirmesi (HTA), kanıta dayalı karar alma süreçlerinde önemli bir araç olarak öne çıkmış, sağlık kaynaklarının verimli kullanımıyla yenilikçi tedavilere sürdürülebilir erişimi desteklemiştir. Ancak, bu süreçlerin etkili kalabilmesi için, sürekli olarak güncellenmesi ve iyileştirilmesi gerekmektedir. Bu tür çabalar yalnızca sektöre değil, aynı zamanda hastalara ve topluma da önemli faydalar sağlayacaktır.</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>Health technology assessment (HTA)</kwd>
                                                    <kwd>  market access</kwd>
                                                    <kwd>  pharmaceutical</kwd>
                                                    <kwd>  pricing</kwd>
                                                    <kwd>  reimbursement</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="tr">
                                                    <kwd>Fiyatlandırma</kwd>
                                                    <kwd>  geri ödeme</kwd>
                                                    <kwd>  ilaç</kwd>
                                                    <kwd>  pazara erişim</kwd>
                                                    <kwd>  sağlık teknolojisi değerlendirmesi (STD)</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. 	Lakdawalla, D.N. (2018). Economics of the pharmaceutical industry. Journal of Economic Literature, 56(2), 397-449. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2. 	Doneski, L., Dong, M. (2023). Pharmaceutical regulations: An overview for the analytical chemist. LCGC North America, 41(06), 211-215. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3. 	Yıldırım, H.H., Mestanoğlu, M. (2019). Competitiveness in Turkey the pharmaceutical industry. IBAD Sosyal Bilimler Dergisi, 340-352. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4. 	Kisa, A. (2006). Analysis of the pharmaceuticals market and its technological development in Turkey. International Journal of Technology Assessment In Health Care, 22(4), 537-542. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5. 	Tokgöz, T. (2010). The Turkish pharmaceutical market. Journal of Generic Medicines, 7(3), 270-274. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6. 	Ercan, T., Top, M. (2016). İlaç tanıtım ve pazarlama faaliyetlerinin önemi. Cumhuriyet Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 1(2), 1-7.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. 	İEİS Web site. (2023). From https://www.ieis.org.tr/tr/turkiye-ilac-sektoru-raporu. Accessed date: 10.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. 	Yumrukaya, L., Postma, M.J., Sözen-Şahne, B., Yeğenoğlu, S. (2022). Recommendations on pharmacoeconomic guidelines for Turkey considering reference countries: A scoping review. Health Policy and Technology, 11(4), 100682. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. 	Atikeler, E.K., Leufkens, H.B., Goettsch, W. (2020). Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad. International Journal of Technology Assessment in Health Care, 36(6), 585-591. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. 	Mashaki Ceyhan, E., Walker, S., Salek, S. (2020). Patients’ perspectives of the pharmaceutical regulatory and reimbursement systems in Istanbul, Turkey. Therapeutic Innovation &amp; Regulatory Science, 54, 1086-1096. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. 	Yenilmez, F.B. (2016) Market Access in Turkey. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Emerging Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. 	Erdağ, E.,L. Yumrukaya, L., Yeğenoğlu, S. (2023). İlaç fiyatlandırma yöntemleri ve dünyadan Türkiye&#039;ye bir yansıma: Geleneksel derleme. Journal of Literature Pharmacy Sciences, 12(3), 201-209. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. 	Demir, C., Şahin B. (2021). Türkiye’de uygulanan ilaç politikaları konusunda paydaşların görüş ve tercihlerinin çok kriterli karar verme yöntemi (Electre Iii) ile değerlendirilmesi. Sosyal Güvence, (20), 565-591. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. 	Kahveci, R., Oortwijn, W., Godman, B., Meltem Koç, E., Tibet, B. (2018). Role of Health Technology Assessment In Pharmaceutical Market Access In Developed Countries. In: G. Kockaya and A. Wertheimer (Eds.), Pharmaceutical Market Access In Developed Countries, (pp. 223-254). Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. 	Toumi, M., S. Jarosławski. (2018) Introduction to Market Access. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access In Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. 	Thomas, D., John, D., Ashoush, N., Lega, F., Li, H. (2019). Market Access, Pharmaceutical Pricing, and Healthcare Costs. In Clinical Pharmacy Education, Practice and Research, pp. 249-259. Elsevier.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. 	RX Communications Web site. From https://www.rxcomms.com/learning/guide-to-market-access-in-the-pharmaceutical-industry. Accessed date: 12.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. 	Balk, S., Schmid C., Gürtler F. (2022). Market Access in Pharma. Campana &amp; Schott.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. 	Acar, A., Yeğenoğlu, S. (2006). Sağlık ekonomisi perspektifinden farmakoekonomi. Hacettepe University Journal of the Faculty of Pharmacy, (1), 39-56.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. 	Tengiz, İ., Atila, D., Ercan, E. (2023). Market distributions and pricing/reimbursement policies of antihypertensive drugs in Türkiye. Türk Kardiyoloji Derneği Arşivi, 51(5), 299-303. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. 	Resmi Gazete (11.12.2021, Sayı: 31686). Beşeri Tıbbi Ürünler Ruhsatlandırma Yönetmeliği, 2021. Accessed date: 1.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. 	TÜSEB. İlaç Geliştirmede Preklinik Araştırmalar ve Ruhsatlandırma Süreçleri Paneli. Youtube [Panel]. 2024.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. 	Csanádi, M., Kaló, Z., Prins, C.P., Grélinger, E., Kiss, A.M., Fricke, F.U., Garrison, L.P. (2018). The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology, 7(3), 243-250. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. 	OECD (2008), Pharmaceutical Pricing Policies in a Global Market, OECD Health Policy Studies, OECD Publishing, Paris. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. 	WHO guideline on country pharmaceutical pricing policies, second edition. Geneva: World Health Organization; 2020.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. 	Resmî Gazete (14.02.2004, Sayı: 25373) Beşeri İlaçların Fiyatlandırılmasına Dair Karar; 2004. Erişim tarihi: 2.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27. 	Murat, O., Özçelikay, G. (2017). Ethical overview of pharmaceutical industry policies in Turkey from various perspectives. Turkish Journal of Pharmaceutical Sciences, 14(3), 264. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. 	Semin, S., &amp; Güldal, D. (2008). Globalization of the pharmaceutical industry and the growing dependency of developing countries: The case of Turkey. International Journal of Health Services, 38(2), 379-398. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">29. 	Gürsoy, K. (2016). An analysis of public pharmaceutical policy, pricing and spending in Turkey. Sosyal Güvenlik Dergisi, 6(1), 225-243.</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">30. 	Bayram, D., Aydın, V., Vızdıklar, C., Akıcı, A. (2021). Trends in generic drug use in Turkey and in the world. Journal of Literature Pharmacy Sciences, 10(2). [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref31">
                        <label>31</label>
                        <mixed-citation publication-type="journal">31. 	Resmi Gazete (06.02.2017, Sayı: 29989). Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar; 2017. Accessed date: 2.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref32">
                        <label>32</label>
                        <mixed-citation publication-type="journal">32. 	Resmi Gazete (25.08.2022, Sayı: 31934). Sosyal Güvenlik Kurumu İlaç Geri Ödeme Yönetmeliği; 2022. Accessed date: 3.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref33">
                        <label>33</label>
                        <mixed-citation publication-type="journal">33. 	Sosyal Güvenlik Kurumu Website. Retrieved June 26, 2024, from: https://www.sgk.gov.tr/Duyuru. Accessed date: 04.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref34">
                        <label>34</label>
                        <mixed-citation publication-type="journal">34. 	İEİS. Geri Ödeme.  From: https://www.ieis.org.tr/tr/geri-odeme. Accessed date: 04.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref35">
                        <label>35</label>
                        <mixed-citation publication-type="journal">35. 	Uğurlu, M. (2018). Sağlık teknoloji değerlendirmesi ülke uygulamaları ve Türkiye için model önerisi. TC Maliye Bakanlığı Strateji Geliştirme Başkanlığı.</mixed-citation>
                    </ref>
                                    <ref id="ref36">
                        <label>36</label>
                        <mixed-citation publication-type="journal">36. 	Gülpınar, G., Pehlivanlı, A., Babar, Z.U.D. (2024). Pharmacy practice and policy research in Türkiye: A systematic review of literature. Journal of Pharmaceutical Policy and Dractice, 17(1), 2385939. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref37">
                        <label>37</label>
                        <mixed-citation publication-type="journal">37. 	HTA Glossary Website.  From: https://htaglossary.net/health-technology-assessment. Accessed date: 04.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref38">
                        <label>38</label>
                        <mixed-citation publication-type="journal">38. 	O&#039;Rourke, B., Oortwijn, W., Schuller, T. (2020). The new definition of health technology assessment: A milestone in international collaboration. International Journal of Technology Assessment in Health Care, 36(3), 187-190. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref39">
                        <label>39</label>
                        <mixed-citation publication-type="journal">39. 	Türkiye İlaç ve Tıbbi Cihaz Kurumu Web site. İlaçta Sağlık Teknolojileri Değerlendirme.  From: https://www.titck.gov.tr/faaliyetalanlari/ilac/ilacta-saglik-teknolojileri-degerlendirme. Accessed date: 05.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref40">
                        <label>40</label>
                        <mixed-citation publication-type="journal">40. 	Sağlık Hizmetleri Genel Müdürlüğü Web site. STD/HTA Nedir? From: https://shgmargestddb.saglik.gov.tr/TR-64042/stdhta-nedir.html. Accessed date: 05.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref41">
                        <label>41</label>
                        <mixed-citation publication-type="journal">41. 	Kahveci, R., Koç, E.M., Küçük, E.Ö. (2017). Health technology assessment in Turkey. International Journal of Technology Assessment in Health Care, 33(3), 402-408. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref42">
                        <label>42</label>
                        <mixed-citation publication-type="journal">42. 	İlaç Takip Sistemi Web site. İlaç Takip Sistemi (ITS). Retrieved 2019, from https://www.its.gov.tr/its/ilac_takip_sistemi_nedir. Accessed date: 05.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref43">
                        <label>43</label>
                        <mixed-citation publication-type="journal">43. 	Resmi Gazete (03.02.2023, Sayı: 32093). Yurt Dışından İlaç Temini Yönetmeliği; 2023. Accessed date: 06.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref44">
                        <label>44</label>
                        <mixed-citation publication-type="journal">44. 	Türkiye İlaç ve Tıbbi Cihaz Kurumu Web site. (2023). İnsani Amaçlı Erken Erişim Programı Kılavuzu. Retrieved 2023, from https://www.titck.gov.tr/mevzuat/insani-amacli-ilaca-erken-erisim-programi-kilavuzu-27122018172818. Accessed date: 06.10.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref45">
                        <label>45</label>
                        <mixed-citation publication-type="journal">45.	 Bleidt, B.A. (2018) Pharmaceutical Market in the US: a Brief Treatise. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref46">
                        <label>46</label>
                        <mixed-citation publication-type="journal">46. 	Bouteiller, E., Chicoye, A. (2024). Fundamentals of Market Access for Pharmaceuticals. Anthem Press.</mixed-citation>
                    </ref>
                                    <ref id="ref47">
                        <label>47</label>
                        <mixed-citation publication-type="journal">47. 	Holtorf, A.P. (2018) Market Access in Germany. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref48">
                        <label>48</label>
                        <mixed-citation publication-type="journal">48. 	Ammar, H. (2018) Market Access in France. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref49">
                        <label>49</label>
                        <mixed-citation publication-type="journal">49. 	Yenilmez, F.B. (2018) Market Access in the UK. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref50">
                        <label>50</label>
                        <mixed-citation publication-type="journal">50. 	Wong, K. (2018) Market Access in Japan. In: Koçkaya G., Wertheimer A. (Eds), Pharmaceutical Market Access in Developed Markets. Italy: SEEd.</mixed-citation>
                    </ref>
                                    <ref id="ref51">
                        <label>51</label>
                        <mixed-citation publication-type="journal">51. 	Civaner, M. (2012). Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain. Health Policy, 106(3), 225-232. [CrossRef]</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
